REGENXBIO Inc.
RGNX
$6.34
$0.213.43%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -43.96% | 104.54% | 91.30% | 74.95% | 80.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.96% | 104.54% | 91.30% | 74.95% | 80.70% |
| Cost of Revenue | 8.77% | 2.69% | -3.83% | -3.29% | -8.93% |
| Gross Profit | -108.62% | 50.77% | 52.46% | 45.76% | 53.04% |
| SG&A Expenses | 13.77% | 15.70% | 0.78% | -4.97% | -11.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -78.12% | -79.31% | 538.67% | 179.28% | 176.97% |
| Total Operating Expenses | 9.69% | 5.43% | -2.52% | -3.50% | -9.43% |
| Operating Income | -63.13% | 30.29% | 35.47% | 32.25% | 39.49% |
| Income Before Tax | -83.91% | 14.63% | 25.55% | 27.22% | 39.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.91% | 14.63% | 25.50% | 27.17% | 39.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.91% | 14.63% | 25.50% | 27.17% | 39.38% |
| EBIT | -63.13% | 30.29% | 35.47% | 32.25% | 39.49% |
| EBITDA | -70.60% | 32.30% | 37.75% | 34.19% | 41.76% |
| EPS Basic | -79.85% | 18.59% | 31.22% | 34.76% | 47.12% |
| Normalized Basic EPS | -79.85% | 17.77% | 29.44% | 33.15% | 45.95% |
| EPS Diluted | -79.92% | 18.59% | 31.22% | 34.79% | 47.18% |
| Normalized Diluted EPS | -79.84% | 17.77% | 29.44% | 33.15% | 45.95% |
| Average Basic Shares Outstanding | 1.83% | 4.18% | 7.47% | 10.98% | 14.91% |
| Average Diluted Shares Outstanding | 1.79% | 4.22% | 7.50% | 11.02% | 14.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |